AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02265679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, high dose, adult patients
Study NCT02265679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02331511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administration for 3 months after device(PPM,ICD,CRT) implantation
Study NCT02331511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 80 mg daily
Description: Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
Study NCT02331511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg daily
Description: Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
Study NCT00948792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short platelet transfusion
Description: 15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
Study NCT00948792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long platelet transfusion
Description: 15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
Study NCT00284518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
Study NCT02739477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results.
Study NCT01269125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: single injection of 3.75 leuprolide every 28 days, 3 dosages
Study NCT00284518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
Study NCT03574051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
Study NCT01212276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-028
Description: Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
Study NCT01269125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Assisted Reproduction Technique.
Study NCT02625519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary follicle-stimulating hormone
Description: Ovarian stimulation with highly purified urinary follicle-stimulating hormone
Study NCT02625519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone
Description: Controled ovarian stimulation with recombinant follicle-stimulating hormone
Study NCT03411733 — intervention group
Intervention type: OTHER
Intervention: Blood and stool samples collection
Description: Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
Study NCT02021422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: anakinra
Description: Dosage Route Administration 100 mg SC Every Other Day
Study NCT02021422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 2-4 hours
Study NCT02021422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 180 mg/m2 90 minutes
Study NCT02021422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Description: fluorouracil 2400 mg/m2 48 hours
Study NCT04628871 — intervention group
Intervention type: BIOLOGICAL
Intervention: SB-318
Description: No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
Study NCT04628871 — intervention group
Intervention type: BIOLOGICAL
Intervention: SB-913
Description: No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
Study NCT02422147 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation of PCL
Description: All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
Study NCT03805633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
Study NCT02596490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Discussion Sessions
Description: Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped.
Study NCT03805633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pancreas
Description: Ultrasound of pancreas will be obtained on all study participants.
Study NCT02272335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: 10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain
Study NCT02272335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Sessions
Description: 10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain
Study NCT04249765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessing grasping force, pinch force,
Description: Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table.
Study NCT03181386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
Study NCT03181386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran and Apixaban
Description: Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
Study NCT03181386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
Study NCT04627844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate Feeding
Description: Standard tube feeds begun at an earlier time point
Study NCT04627844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Feeding
Description: Standard tube feeds begun at delayed time point
Study NCT03415867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
Study NCT02749604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ejaculatory sparring PVP
Description: Greenlight laser photoslective vaporization of the prostate
Study NCT02749604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ejaculatory sparring PVP
Description: Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
Study NCT00577655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
Study NCT00577655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA MDI four times a day (q.i.d) for 21 days.
Study NCT00577655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proventil® HFA
Description: Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
Study NCT00577655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proventil® HFA
Description: Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
Study NCT02054819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Induction chemotherapy and concurrent radiation
Description: Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
Study NCT02054819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consolidation: Radiation therapy to metastatic sites
Description: At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
Study NCT01159145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H
Description: Oral, capsule
Study NCT01159145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral, tablet
Study NCT00712816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready Injury Treatment System (CoolSystems Inc.)
Description: Cold with intermittent compression postoperatively for 2 weeks
Study NCT00712816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice with compressive bandages
Description: Cold with static compression postoperatively for 2 weeks
Study NCT02244190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: New oral solution (back up) formulation
Study NCT02244190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipranavir
Study NCT02244190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Study NCT02244190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02596490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer-Related Discussion Program
Description: Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
Study NCT04506775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViTrack
Description: ViTrack is a continuous non-invasive wearable blood pressure cuff.
Study NCT04506775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization
Description: Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
Study NCT00748722 — intervention group
Intervention type: DEVICE
Intervention: CT Angiography
Description: Injection of contrast material (iodine)
Study NCT06720012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific instrumentation (PSI)
Description: Cutting guides that are manufactured using advanced imaging and modelling techniques to create instruments that align more closely with the unique anatomy of each patient. Custom guides were created based on a preoperative MRI protocol (Zimmer Patient Specific Instrumentation for NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States in collaboration with Materialise NV, Leuven, Belgium) to optimize the placement of the components without the need for intramedullary alignment.
Study NCT06720012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional instruments
Description: Instruments specific to the implant that are used to guide bone cutting in reference to the intramedullary canal or using an extramedullary jig.
Study NCT06720012 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Total Knee Arthroplasty
Description: A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
Study NCT06720012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cemented Total Knee Arthroplasty
Description: A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
Study NCT01956318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crenobalneotherapy
Description: 18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
Study NCT00870116 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT by cyberknife
Description: treatment = 2x15 Gy during 2 weeks
Study NCT00870116 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT by linear accelerator
Description: treatment = 2x15 Gy during 2 weeks
Study NCT00870116 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Conformational radiotherapy
Description: treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
Study NCT00627744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
Study NCT00627744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
Study NCT06322485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-management intervention
Description: An internet-based cognitive-behavioral therapy with six modules.
Study NCT04341883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1+Albumin-Bound Paclitaxel
Description: anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody
Study NCT04492930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 14:10 Regimen
Description: 14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
Study NCT04492930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12:12 Regimen
Description: 12 hours of fasting, followed by a 12-h diet regimen
Study NCT00503867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres
Description: SIR-Spheres Yttrium-90 microspheres
Study NCT01754935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet
Study NCT01754935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-509 matching placebo
Description: 0 mg oral tablet
Study NCT03552328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lunch with Medical Student
Description: Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
Study NCT03552328 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
Study NCT05751447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lymph node puncture, bronchoscopy
Description: Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
Study NCT04750681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects orally ingested, with water, one capsule per day (in the evening)
Study NCT04750681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffron
Description: Subjects orally ingested, with water, one capsule per day (in the evening)
Study NCT01591720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-based CBT for depression and anxiety
Description: This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
Study NCT02018263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine hydrochloride
Study NCT02018263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT02018263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Study NCT01531790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: d1, AUC 5, i.v.
Study NCT01531790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: d1, 500 mg/m2, i.v.
Study NCT01341990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Description: Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
Study NCT01341990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)
Description: Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses